SEMINARS IN ARTHRITIS AND RHEUMATISM, vol.48, no.3, pp.467-474, 2018 (SCI-Expanded)
Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.